Barbara Fahey
Family · Weirton, WVNPI 1689671703
Payments from drug & device makers
Across 100 payments — averaging $27.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$671
- AbbVie$571
- Xeris Pharmaceuticals, Inc.$229
- GSK$217
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$191
- Johnson & Johnson$123
- plus $748 from 22 others
What the payments were for
- Food & beverage$2,750100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $671 |
| AbbVie | 22 | $571 |
| Xeris Pharmaceuticals, Inc. | 2 | $229 |
| GSK | 9 | $217 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $191 |
| Johnson & Johnson | 2 | $123 |
| Lilly USA, LLC | 5 | $90 |
| Pfizer | 4 | $75 |
| Scpharmaceuticals Inc. | 1 | $64 |
| Merck | 3 | $58 |
| Boehringer Ingelheim | 3 | $54 |
| Amgen | 3 | $49 |
| Corcept Therapeutics | 2 | $35 |
| Edwards Lifesciences | 1 | $33 |
| Hologic Sales And Service, LLC | 1 | $29 |
| AstraZeneca | 2 | $28 |
| Exact Sciences | 2 | $27 |
| Organon | 2 | $22 |
| Lundbeck LLC | 1 | $22 |
| Bayer | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
| VBI Vaccine (delaware) Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Phadia US Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Gilead | 1 | $13 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,750 in reported general payments places this provider in the 85th percentile of 1,507 family providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 131 | $132,558 |
| JanuviaSitagliptin Phosphate | 78 | $99,621 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 50 | $42,297 |
| MounjaroTirzepatide | 27 | $29,755 |
| XifaxanRifaximin | 11 | $28,844 |
| JardianceEmpagliflozin | 32 | $27,127 |
| Nurtec OdtRimegepant Sulfate | 14 | $26,694 |
| TrulicityDulaglutide | 28 | $25,481 |
| XareltoRivaroxaban | 21 | $23,863 |
| RybelsusSemaglutide | 14 | $22,109 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $21,048 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $18,646 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $14,799 |
| Novolog FlexpenInsulin Aspart | 60 | $10,304 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 76 | $10,146 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $671 | $154,667145 claims |
| MerckJanuvia | $58 | $99,62178 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Arnuity Ellipta | $217 | $69,038122 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat, Tradjenta | $54 | $59,32379 claims |
| Lilly USA, LLCMounjaro, Trulicity | $90 | $55,23555 claims |
| PfizerNurtec Odt | $75 | $26,69414 claims |
| Johnson & JohnsonXarelto | $123 | $23,86321 claims |
| AbbVieNamzaric | $571 | $6,72912 claims |
| AstraZenecaSymbicort | $28 | $2,60111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,507 family providers in West Virginia.
Other family in Weirton
- Anthony ReesWeirton$7K
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.